Prof. PeptideProf. Peptide

Glycine

Sleep & Recovery

Last reviewed: May 26, 2026

Also Known As: L-glycine, aminoacetic acid, the simplest amino acid

Supplement Class: Non-essential amino acid / inhibitory neurotransmitter / NMDA receptor co-agonist

Evidence Tier: Moderate — three independent human RCTs (Inagawa et al. 2006, Yamadera et al. 2007, Bannai et al. 2012) demonstrating reduced sleep onset latency and improved subjective sleep quality at 3 g pre-bed, with polysomnography-instrumented confirmation and a cleaner safety profile than most sleep supplements. Small trial samples and limited disease-state replication keep this below Strong tier.

Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

What is glycine?

Glycine is the smallest amino acid the human body uses — a simple, endogenous molecule the body produces and uses for collagen synthesis, neurotransmitter regulation, and one-carbon metabolism. It is also one of the better-supported natural sleep supplements, with three independent human RCTs showing 3 g taken 30–60 minutes before bed reduces sleep onset latency, improves subjective sleep quality, and reduces next-day fatigue. The mechanism is unusual: glycine works primarily through body-temperature regulation rather than direct sedation. It acts at NMDA receptors in the suprachiasmatic nucleus, triggering peripheral vasodilation that lowers core body temperature — one of the strongest biological signals for sleep onset. Unlike antihistamines, benzodiazepines, or even most herbal sleep aids, glycine is not associated with next-morning grogginess; Bannai et al. 2012's trial specifically documented improved next-day psychomotor vigilance after partial sleep restriction. It is discussed as pairing naturally with sleep peptides like DSIP because the mechanisms operate on different layers of sleep biology.

Reported benefits:

  • Reduced sleep onset latency (the most-replicated RCT finding)
  • Improved subjective sleep quality and morning refreshedness
  • Reduced next-day fatigue after partial sleep restriction (Bannai et al. 2012)
  • No next-morning grogginess reported — distinct from sedative-class sleep aids
  • Improved sleep efficiency on polysomnography (Yamadera et al. 2007)
  • Body-temperature regulation via NMDA co-agonism at the SCN
  • Substrate for collagen synthesis (a secondary benefit at higher doses)

Common dose: 3 g (3,000 mg) taken 30–60 minutes before bed — the dose used in every positive human sleep RCT. Powder form is the practical default (faintly sweet, easy to dose in water). Higher doses (6–9 g) have been tested for safety but don't clearly add sleep benefit.

Reported safety considerations: Clozapine interaction (avoiding supplemental glycine is standard guidance for this specific medication); other antipsychotics (theoretical NMDA interaction — clinician coordination); additive sedation with other sedatives; limited pregnancy data. Overall, glycine has one of the cleanest safety profiles of any sleep supplement.

On this page

How does glycine work?

Glycine works through two parallel mechanisms that converge on sleep onset. The dominant one is body-temperature regulation: glycine acts at NMDA receptors in the suprachiasmatic nucleus (the master circadian clock), triggering peripheral vasodilation that allows the body to shed heat through the hands and feet. The resulting core-body-temperature drop is one of the strongest biological signals for sleep onset. The secondary arm is direct inhibitory neurotransmission at glycine receptors in the brainstem.

  1. NMDA receptor co-agonism at the SCN. Glycine binds the glycine site of NMDA receptors in the suprachiasmatic nucleus, modulating circadian and thermoregulatory signaling. Kawai et al. 2015 demonstrated this using site-specific receptor pharmacology — the clearest mechanistic explanation for the human sleep findings.
  2. Peripheral vasodilation and core-body-temperature drop. SCN activation triggers vasodilation in the hands and feet, allowing heat to dissipate and core temperature to fall. Sleep onset is tightly coupled to the core-temperature drop curve, and glycine is discussed as pre-positioning the body on that curve.
  3. Inhibitory neurotransmission. At glycine receptors in the brainstem and spinal cord, glycine acts as an inhibitory neurotransmitter — the same receptor family targeted by strychnine antagonism. This inhibitory tone contributes to muscle relaxation and may modulate arousal, though this arm is mechanistically secondary to the temperature effect for sleep.
  4. Modest changes in sleep architecture. Polysomnography data (Yamadera et al. 2007, Bannai et al. 2012) show glycine reduces sleep onset latency and increases sleep efficiency. REM sleep architecture is preserved or modestly improved, distinct from sedatives that suppress REM. Slow-wave sleep changes are inconsistent across trials.
  5. Daytime cognitive buffering. Bannai et al. 2012's follow-up demonstrated improved next-day psychomotor vigilance after partial sleep restriction. The mechanism is likely indirect: better-quality sleep is reported to produce better next-day cognition, even when total sleep time is held constant.

What does the evidence say glycine does?

Glycine has one of the cleaner small-RCT evidence bases of any sleep supplement. The Inagawa et al. 2006, Yamadera et al. 2007, and Bannai et al. 2012 trial sequence consistently shows reduced sleep onset latency, improved subjective sleep quality, and reduced next-day fatigue in healthy adults with mild sleep complaints. Effect sizes are modest in absolute terms but consistent across independent measurement methods — subjective questionnaires, polysomnography, and PVT.

  1. Sleep onset latency (Strong). 3 g glycine 30–60 minutes pre-bed consistently reduces time to fall asleep across all three major human RCTs. Polysomnography (Yamadera et al. 2007) confirms the subjective finding.
  2. Subjective sleep quality (Strong). Inagawa et al. 2006 documented significant improvements in self-reported sleep quality and morning refreshedness, replicated in Yamadera et al. 2007 and Bannai et al. 2012.
  3. Next-day fatigue and cognitive performance (Moderate). Bannai et al. 2012 specifically measured next-day function under partial sleep restriction; the glycine group reported less fatigue and better PVT performance than placebo — relevant for populations facing partial and predictable sleep loss, such as shift workers, new parents, and travelers.
  4. Sleep architecture changes (Moderate). Polysomnography shows improved sleep efficiency and reduced sleep onset latency. REM sleep is preserved; slow-wave sleep changes are inconsistent.
  5. Diagnosed insomnia (Unestablished). All published RCTs are in healthy adults with mild complaints, not diagnosed insomnia disorder. The case for clinical insomnia is mechanistically plausible but not directly supported by trial data.

How is glycine dosed?

Glycine dosing is unusually simple: 3 grams pre-bed is the dose used in every published positive trial. Higher and lower doses have been tested, but the 3 g range is what every effective RCT uses. The taste is faintly sweet and reported as palatable in water, making powder the practical default.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

  1. Standard sleep dose. 3 g (3,000 mg) glycine taken 30–60 minutes before bed — the dose used in Inagawa et al. 2006, Yamadera et al. 2007, and Bannai et al. 2012.
  2. Light starter dose. 1–2 g pre-bed for a tolerance check or sensitive users. This sits below the RCT-validated range and may underperform but is a reasonable initial trial dose.
  3. High dose. 6–9 g has been tested in safety studies with no concerning signal but no clear additional sleep benefit. There is no established reason to exceed 3 g routinely.
  4. Connective-tissue / collagen support. 5–10 g daily (often split AM/PM) is discussed for users targeting glycine's collagen-precursor role rather than sleep — a different use case with different dosing.

Reported timeline: most users notice improved sleep onset and morning refreshedness within 2–3 nights. No loading phase is needed — the body-temperature mechanism is reported to operate the night it's taken.

Label math. A level teaspoon of pure glycine powder is approximately 3 g. Capsules are typically 500–1000 mg, requiring 3–6 capsules to reach the research dose. Powder is the practical default for cost and convenience.

How glycine is taken

Glycine is taken orally, almost always as powder dissolved in water. The taste is faintly sweet and reported as clean, without needing to be masked. The practical details below cover what the trial protocols and experienced use converge on.

AspectReported
FrequencyOnce nightly for sleep; 1–2× daily if also targeting collagen/connective-tissue support.
Best time of day30–60 minutes before bed for the sleep protocol, allowing time for the body-temperature drop to develop. Earlier dosing may produce mild drowsiness; avoiding pre-driving doses on first use is standard guidance.
FoodAn empty stomach is fine and possibly preferred, since absorption is fast and food isn't required. Heavy meals just before bed work against the sleep goal regardless.
FormPowder is generally preferred (mild taste, easy dosing, lower cost); capsules work but require 4–6 large caps for 3 g; liquid formulations exist but offer no advantage over powder in water.
Standardization marker“L-glycine” or “pharmaceutical-grade glycine” as the single active ingredient, third-party tested (USP, NSF, ConsumerLab), are the markers discussed; proprietary blends make precise dosing difficult.
CyclingNo cycling is needed — nightly use is the studied protocol, and tolerance development is not a documented concern.

What does glycine stack with?

Glycine is one of the easier sleep supplements to stack — the body-temperature mechanism doesn't conflict with GABAergic, circadian, or peptide-level sleep interventions. The three areas below cover the natural stacking categories.

With peptides

Glycine pairs naturally with the Russian-origin sleep and cognitive peptide cluster. DSIP (delta sleep-inducing peptide) is discussed as operating directly on slow-wave sleep architecture — a peptide-level intervention at a different layer than glycine's body-temperature mechanism. Selank (a tuftsin analog) provides anxiolytic effects via GABA modulation — relevant when sleep is blocked by anxious arousal rather than circadian or thermal issues. Glycine addresses the sleep-onset thermoregulation and inhibitory neurotransmission arms. The mechanisms are complementary, with no known negative interactions documented; introducing one variable at a time when starting a new stack is standard guidance for isolating what's producing an effect.

With supplements

  1. Magnesium glycinate — discussed for GABAergic and neuromuscular relaxation. The glycinate form already contains some glycine but at sub-RCT doses; the full 3 g glycine dose is typically stacked separately.
  2. Melatonin — a circadian signal (low-dose 0.3–0.5 mg). A different mechanism, generally compatible: glycine is discussed as supporting sleep onset; melatonin signals circadian timing.
  3. Apigenin — a GABA-A positive allosteric modulator. Complements glycine's inhibitory-neurotransmitter arm; both target sleep onset via different receptor families.
  4. L-theanine — associated with alpha-wave relaxation; useful pre-bed for mental chatter, complementing the thermoregulation arm.
  5. Tart cherry — an endogenous melatonin precursor profile plus anti-inflammatory effects on sleep; a compatible chronic-use pairing.

With lifestyle factors

  1. A warm shower or bath 60–90 minutes pre-bed. The same thermoregulation logic as glycine — the post-bath cool-down accelerates the core-temperature drop, a natural pairing.
  2. A cool bedroom (roughly 65–68°F / 18–20°C). Supports the heat-shedding step glycine facilitates; hot bedrooms are discussed as blunting glycine's mechanism.
  3. A consistent sleep schedule. Glycine works on top of circadian alignment, not as a substitute; variable bedtimes erode the body-temperature curve glycine is designed to ride.
  4. Partial sleep restriction buffering. Bannai et al. 2012 specifically documented glycine's benefit on next-day function after curtailed sleep — relevant for known short-sleep nights such as travel, shift work, or parenting.

Side effects and interactions

Glycine has one of the cleanest safety profiles of any sleep supplement. Acute doses up to 9 g have been tested without serious adverse events. The main practical considerations are mild GI effects at high doses and one specific psychiatric drug interaction.

Common (mostly transient)

  1. Mild GI discomfort — soft stools or mild nausea at higher doses (5 g+), generally resolving with dose reduction.
  2. Drowsiness if dosed too early — the body-temperature drop can produce mild somnolence; avoiding driving after a 3 g dose is standard guidance.
  3. A sweet aftertaste — glycine is faintly sweet, reported as pleasant by some users and mildly off-putting by others.

Less common (watch-list)

  1. Vivid dreams — occasionally reported, plausibly tied to preserved or extended REM during the cooling phase.
  2. No documented serious adverse events at the standard 3 g dose across the published RCT base.

Drug and supplement interactions

  1. Clozapine (antipsychotic). Avoiding supplemental glycine is standard guidance — glycine can interfere with clozapine's efficacy via NMDA-receptor mechanisms; this is the one well-documented contraindication.
  2. Other antipsychotics — a theoretical NMDA interaction concern; coordinating with the prescribing clinician is standard guidance for chronic antipsychotic therapy.
  3. Sedatives (benzodiazepines, Z-drugs, antihistamines) — additive mild sedation is possible; not a contraindication but watching total sedation load on first use is standard guidance.
  4. Other sleep supplements — generally compatible (see the Stacks section); the main caution is over-dosing total inhibitory tone if multiple GABAergic and glycinergic agents are stacked aggressively.
  5. Pregnancy — limited data; clinician consultation is standard guidance. Glycine is endogenous and food-abundant, but supraphysiological supplemental doses in pregnancy aren't well-characterized.

What isn't established about glycine

Glycine has a clean small-RCT base, but several open questions remain — particularly around clinical insomnia transfer, long-term high-dose safety, and the gap between healthy-adult evidence and disease-state populations.

Clinical insomnia evidence. All published positive trials are in healthy adults with mild-to-moderate sleep complaints, not diagnosed primary insomnia or chronic insomnia disorder. Whether 3 g glycine moves the needle in clinical insomnia is genuinely unknown. CBT-I remains first-line for chronic insomnia; glycine is discussed as a reasonable adjunct, not a substitute.

Long-term daily safety at supplemental doses. Published trials run from a single night to a few weeks. Multi-year nightly 3 g use isn't characterized in controlled trials. The current best inference is that 3 g/night appears safe based on tolerability and short-term data, but the long horizon is unstudied.

Effect-size variability. Sample sizes are small (10–20 subjects per trial), and effect sizes are modest in absolute terms — glycine is not a sedative. Some users report a robust response; others see no measurable difference. The trial base doesn't identify which subgroups respond best.

Sleep-architecture specificity. Polysomnography data is positive on sleep onset and efficiency, but slow-wave sleep changes are inconsistent across trials. Whether glycine meaningfully alters deep-sleep architecture, or only sleep-onset speed, isn't fully resolved.

Dose-response above 3 g. 6 g and 9 g have been tested for safety but not for sleep efficacy versus 3 g. Whether higher doses produce larger or no additional sleep benefit is unknown.

Where studies disagree. The published trial base is small and largely from Japan (Inagawa, Yamadera, and Bannai — an overlapping author/collaboration network). Independent replication outside the original group is limited. The directional signal across the small corpus is consistent, but the heterogeneity of the source is real.

Where to buy glycine

Glycine is one of the easier supplements to source — pharmaceutical-grade product is widely available at low cost, since the molecule is simple and verification is straightforward. The quality markers below are the screen discussed for this category.

Quality markers reported in the category

  • Pharmaceutical-grade or USP-grade L-glycine as the single active ingredient.
  • Third-party testing — USP, NSF, or ConsumerLab certifications signal independent verification.
  • cGMP-certified manufacturing facility — a baseline quality marker for any supplement.
  • Avoiding proprietary blends or sleep-stack mixes that obscure the actual glycine dose is standard guidance for dosing precisely.
  • Powder form is generally preferred — cheaper per gram, easier to dose at 3 g, and palatable in water.
  • No unnecessary additives — pure glycine is faintly sweet on its own, without needing flavorings, sweeteners, or fillers.
  • A price premium doesn't signal better quality here — glycine is one of the cheapest amino acids to produce.
Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

Glycine FAQ

How much glycine is typically used for sleep?

3 grams (3,000 mg), 30–60 minutes before bed, is the dose used in every major human RCT (Inagawa et al. 2006, Yamadera et al. 2007, Bannai et al. 2012). Higher doses (6 g, 9 g) have been tested in safety studies with no concerning signal but no clear additional sleep benefit. Lower doses (1–2 g) are not well-characterized in sleep trials — they may work for some users, but that range sits below the RCT-validated dose.

Does glycine cause morning grogginess?

Generally not — and that is the most distinguishing feature of glycine relative to other sleep aids. Bannai et al. 2012's follow-up trial specifically measured next-day fatigue and psychomotor vigilance after partial sleep restriction; the glycine group showed reduced fatigue and better psychomotor vigilance test (PVT) performance versus placebo. The body-temperature mechanism, rather than receptor-level sedation, is the likely reason — glycine is associated with faster sleep onset and more efficient sleep without the next-morning sedation tail reported with antihistamines or benzodiazepines.

How long does glycine take to start working?

Most users report changes within the first 2–3 nights of consistent use, and the published RCTs measured effects within the first week. Glycine isn't a habit-builder in the way melatonin is often discussed — the body-temperature effect is reported to operate the night it's taken. If 3 g pre-bed for 7–10 nights produces no noticeable change, glycine is likely not an effective lever for that individual, and pushing the dose higher in hope of a delayed effect is not supported by the trial evidence.

Can glycine be combined with melatonin or magnesium glycinate?

Yes — they target different layers of sleep biology. Melatonin is a circadian signal (when to sleep); magnesium glycinate is discussed for GABAergic and neuromuscular relaxation; glycine acts on body-temperature regulation and inhibitory neurotransmission. No known interactions between the three are documented. Worth noting: magnesium glycinate already contains some glycine, but a typical 200 mg magnesium glycinate dose provides only around 1 g of glycine — well below the 3 g sleep dose used in the trials. Stacking the two still calls for the full 3 g glycine dose pre-bed.

Can glycine be stacked with DSIP or Selank?

Yes — the combination is mechanistically complementary, addressing different layers of sleep and recovery. DSIP (delta sleep-inducing peptide) is discussed as modulating slow-wave sleep architecture directly — a peptide-level intervention on sleep depth. Selank is a tuftsin analog with anxiolytic effects via GABA modulation — relevant when sleep is blocked by anxious arousal rather than circadian or thermal issues. Glycine addresses the body-temperature drop and sleep-onset latency arm, RCT-validated in healthy adults with mild sleep complaints. The mechanisms are distinct and compatible, with no known negative interactions documented.

Does glycine help diagnosed insomnia, or only mild sleep issues?

The honest answer is that the RCT base is in healthy adults with mild-to-moderate sleep complaints, not diagnosed primary insomnia or chronic insomnia disorder. Sample sizes were small (10–20 subjects per trial), durations were short (a single night to a few weeks), and severity was mild. Whether glycine moves the needle in clinical insomnia is genuinely unknown from the available evidence — it might, but the trial data doesn't establish that case. For chronic insomnia, CBT-I remains the first-line intervention with the strongest evidence; glycine is discussed as a reasonable adjunct, not a substitute.

Is glycine derived from animal sources? Is it vegan?

Most commercial supplemental glycine is produced via industrial fermentation or chemical synthesis, making it vegan-suitable regardless of supplier in nearly all cases. Glycine is also naturally abundant in collagen-rich foods (bone broth, skin, gelatin, connective tissue), which is why traditional bone-broth cooking provides a meaningful glycine dose. Plant-based food sources — beans, lentils, sesame seeds, and pumpkin seeds — are available for those avoiding animal collagen sources, though they provide far less glycine per serving.

Is powder or capsule form generally preferred?

Powder is generally preferred. Glycine has a faintly sweet taste that's reported as pleasant in water, and a 3 g serving is roughly a level teaspoon, making it easy to measure. Reaching 3 g from capsules requires 4–6 large capsules (most are 500 mg), which is less convenient for nightly use. Powder is also typically cheaper per gram. Capsules are more practical for travel or shared storage, where a sealed bottle is more convenient than a powder tub.

References

  1. Inagawa K, Hiraoka T, Kohda T, Yamadera W, Takahashi M. Subjective effects of glycine ingestion before bedtime on sleep quality. Sleep Biol Rhythms. 2006;4(1):75-77. https://onlinelibrary.wiley.com/doi/10.1111/j.1479-8425.2006.00193.x
  2. Yamadera W, Inagawa K, Chiba S, Bannai M, Takahashi M, Nakayama K. Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes. Sleep Biol Rhythms. 2007;5(2):126-131. https://onlinelibrary.wiley.com/doi/10.1111/j.1479-8425.2007.00262.x
  3. Bannai M, Kawai N, Ono K, Nakahara K, Murakami N. The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. Front Neurol. 2012;3:61. https://pubmed.ncbi.nlm.nih.gov/22529837/
  4. Bannai M, Kawai N. New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep. J Pharmacol Sci. 2012;118(2):145-148. https://pubmed.ncbi.nlm.nih.gov/22293292/
  5. Kawai N, Sakai N, Okuro M, Karakawa S, Tsuneyoshi Y, Kawasaki N, Takeda T, Bannai M, Nishino S. The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus. Neuropsychopharmacology. 2015;40(6):1405-1416. https://pubmed.ncbi.nlm.nih.gov/25533534/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Sleep and Biological Rhythms · 2006Paywalled
Subjective Effects of Glycine Ingestion Before Bedtime on Sleep Quality →

Inagawa K, Hiraoka T, Kohda T, Yamadera W, Takahashi M

A randomized placebo-controlled crossover trial of 3 g glycine before bed in adults with mild sleep complaints. Glycine significantly improved subjective sleep quality, reduced sleep onset latency, and reduced morning fatigue versus placebo — the first major published RCT to demonstrate glycine's sleep effect in humans and the trial that established the 3 g pre-bed protocol used in nearly all subsequent research.

Sleep and Biological Rhythms · 2007Open Access
Glycine Ingestion Improves Subjective Sleep Quality in Human Volunteers, Correlating with Polysomnographic Changes →

Yamadera W, Inagawa K, Chiba S, Bannai M, Takahashi M, Nakayama K

A polysomnography-instrumented RCT of 3 g glycine before bed in healthy adults with occasional sleep complaints. Glycine reduced sleep onset latency and improved sleep efficiency, with polysomnographic data confirming changes in actual sleep architecture rather than only subjective perception — the arm that elevated glycine's evidence base beyond self-reported sleep quality alone.

Frontiers in Neurology · 2012Open Access
Effects of Glycine on Subjective Daytime Performance in Partially Sleep-Restricted Healthy Volunteers →

Bannai M, Kawai N, Ono K, Nakahara K, Murakami N

An RCT examining next-day performance after partial sleep restriction (25% sleep curtailment) with 3 g glycine versus placebo. Glycine reduced subjective fatigue and improved psychomotor vigilance test (PVT) performance the following day — evidence that glycine's benefit extends beyond the night of supplementation, buffering the cognitive cost of insufficient sleep in contexts like travel, shift work, or parenting.

Neuropsychopharmacology · 2015Open Access
The Sleep-Promoting and Hypothermic Effects of Glycine Are Mediated by NMDA Receptors in the Suprachiasmatic Nucleus →

Kawai N, Sakai N, Okuro M, Karakawa S, Tsuneyoshi Y, Kawasaki N, Takeda T, Bannai M, Nishino S

A mechanistic study in rats using site-specific NMDA receptor pharmacology, demonstrating that glycine's sleep-promoting and body-temperature-lowering effects depend on NMDA receptors in the suprachiasmatic nucleus (the master circadian clock). This provides the mechanistic explanation for the human RCT findings: glycine acts as an NMDA co-agonist at the SCN, triggering peripheral vasodilation and the core-body-temperature drop that signals sleep onset.

Journal of Pharmacological Sciences · 2012Open Access
New Therapeutic Strategy for Amino Acid Medicine: Glycine Improves the Quality of Sleep →

Bannai M, Kawai N

A review of the glycine sleep literature through 2012, covering the Inagawa, Yamadera, and Bannai trials in detail, the body-temperature mechanism, the NMDA co-agonist arm, and safety data through 9 g acute dosing — a single-source summary framing the human RCT literature.

Amino AcidSleep OnsetBody TemperatureNext-Day AlertnessNMDA Co-Agonist3g Protocol

We may earn commissions from peptide vendor affiliate links.

Have a question about Glycine? Send us an email